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INTRODUCTION:
Diabetes Mellitus is a group of metabolic diseases
characterized by increase in blood glucose levels. The
pathophysiology of diabetes includes defects in insulin
secretion, insulin action, or both. Chronic hyperglycemia
of diabetes is associated with damage, malfunction and
failure of various organs including eyes, kidneys, nerves,
heart, and blood vessels1.
Global prevalence of diabetes has increased up to 6.6%
in recent years. Almost 285 million, people around the
world are affected with this disease.142 million affected
people are males and remaining 143 million are females.
Out of 285 million approximately 108 million have age
range of 60-79 years, 132 million 40-59 years and 44
million 20-39 years of age2.  Pakistani nation is ranked
6th with diabetic burden in the population.3 Changes in
body due to hyperglycemia and hyperinsulinemia in
diabetes can lead to athero-thrombic deposition as well
as lethal changes in the vessels that causes 70-75%
deaths in diabetic patients due to cardiovascular events4,5
Multiple treatments have been used for patients of Type
2 Diabetes Mellitus. Oral drugs include several groups
such as Sulfonylureas, Biguanides, Glitazones,
Maglitinides, DPP-4 inhibitors etc. If control of
hyperglycemia is not attained by oral drugs alone then
injectable agent insulin is also prescribed. Some drugs
which are common in use, are sulfonylureas and
biguanide- metformin, have better compliance than
others. Oral drugs maintain blood glucose level, providing
diabetics cost effective better life through a physiological
route. Metformin is the first line oral anti-diabetic drug
used in type 2 diabetes. It is a euglycemic agent with
additional benefit of decreasing the progression of
vascular adverse effects caused by hyperglycemia6.
Multiple electronic databases PubMed, Science direct,
Google.com and Google scholar were searched by using
key words, terminologies and phrases of diabetes type
2, oral hypoglycemic agents, metformin, euglycemic
agent, metformin effects on vessels, vasculo-protective
effects, endothelial dysfunction, atherosclerosis,
fibrinolysis, carotid intima, and lipoprotein lipase.
Literature search of abstracts, original articles, review
articles and case studies published in past 13 years
(September 2000 - September 2013) was carried out
and is incorporated in the preparation of this review
article after using the filter vasculo-protective effect.
LITERATURE REVIEW:
The vascular endothelium is an important site for control
of almost all vascular events and functions7.  Many
crucial vasoactive endogenous products like prostacyclin,
thromboxane, nitric oxide, angiotensin, endothelium
derived hyperpolarizing factors, free radicals, and
bradykinins are formed in the endothelial cells of vessels
to control the proper functioning of vascular smooth
muscles and of circulating blood cells8.  Many at times
endothelial dysfunctions precede and predict clinical
micro vascular diseases. Multiple studies have proven
the fact that endothelium is both a target and mediator
of atherosclerotic changes leading to cardiovascular
diseases9.  Different pathological events occurring with
diabetes such as change in cholesterol levels,
hypertension, increase in homocystine levels and visceral
fat accumulation are also associated with endothelial
dysfunction10.Other risk factors for vascular diseases in
diabetes could be  increase in plasminogen activator 1,
increase in clotting factor 7, decrease in HDL levels,
increase in triglyceride levels and micro albuminuria11
which further worsen the condition in vascular wall in
type 2 diabetics. The most important of these vasoactive
substances is nitric oxide which is a vasoprotective agent
as it inhibits inflammation, oxidation and proliferation
of vascular smooth muscles. Bioavailability of nitric
oxide plays a very important role in regulation of events
in vessels12. Early markers of endothelial dysfunction
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can be decrease in amounts of nitric oxide leading to
abnormal vasomotor response and subsequently micro
and macro vascular pathology. Different studies have
also indicated the fact that endothelial dysfunction can
be induced by abnormality in the insulin signaling
pathway, that can be a result of deprivation of endothelial
nitric oxide synthase. When taken together it is evident
that in type 2 diabetes, insulin resistance and endothelial
dysfunction are related to each other.  Treating these
two previous issues would definitely improve the latter
ones and therefore the functioning of vascular system13.
Metformin: Metformin is one of the important agents
for controlling hyperglycemia in type 2 diabetes these
days. It has a botanical source, obtained from Galegia
Officianalis; known as goats rue and French lilac. It acts
as a euglycemic agent by decreasing the carbohydrate
absorption and increasing its utilization by decreasing
the insulin resistance.14
Metformin is slowly absorbed from the gut with
elimination half life of 3-6 hours which occur through
kidneys. It does not increase the body weight and can
be used as mono-therapy.15 The side effects encountered
with metformin are metallic taste, anorexia, nausea,
flatulence, abdominal cramp, occasionally diarrhea and
vomiting. All these features usually tend to disappear
with the continuation of therapy. Rarely lactic acidosis
can occur in patients with renal and hepatic insufficiency.
This can be prevented to a large extent by having LFTs
and renal profile of the patients before starting the
therapy.
Metformin mode of action:
Metformin reduces blood glucose level without
increasing the production of insulin, and has greater
glucose lowering efficacy as compared to other anti-
diabetic agents.16 The anti hyperglycemic effect of
metformin is explained by several mechanisms that
collectively balance insulin resistance and improve
glucose homeostasis.17, 18 The two main mechanisms are
inhibition of gluconeogenesis, and improvement in
glucose uptake by decreasing insulin resistance.19
Metformin along with some life style modifications and
weight reduction can be useful for improving the
endothelial function and decreasing the risk of CVS
diseases in diabetics.20, 21
1. Effect of Metformin on smooth muscles :
Many studies have proven the fact that defective insulin
signaling is a factor for vascular problems in type 2 dia-
betic patient. In insulin resistance this pathway gets dis-
turbed and finally there is no nitric oxide dependent rel-
axation of vascular smooth muscles leading to stiffness
and shortening of diameter in these vessels. Metformin
has shown vasculo-protective effects by inhibiting these
above mentioned mechanisms. Metformin improves the
skin capillary reactivity, functional capillary density and
also stimulates slow wave arteriolar vasomotion.22,23 Di-
fferent animal studies have shown improvement in nitric
oxide activity and probable relaxation of pre-contracted
aortic ring in streptozotocin induced diabetic rats.24,25 Ad-
ministration of metformin in the rat tail arteries causes
arterial relaxation due to decrease in activity of intrace-
llular calcium ions. Metformin potentiate the production
of nitric oxide by increasing local nitric oxide synthase
which again decreases the response of calcium ions in
the smooth muscles of the vessels. Finally metformin
decreases constriction and enhances the post ischemic
perfusion of capillary beds.26
2. Effect of metformin on vascular endothelium:
Other than vascular smooth muscles in vessels, endo-
thelium is also an important part where vascular defo-
rmity is noticed at an early stage in diabetics.  In recent
years insulin resistance and endothelium has been of
great interest to the researchers due to a strong relati-
onship between diabetics and endothelial abnormalities.
Metformin increases endothelial dependent vasodilation,
independent of its glycemic control properties. The main
mechanism behind this effect is the increase in nitric
oxide synthase and nitric oxide precursor L-arginine
which is an amino acid.
3. Effects of metformin on monocyte adhesion:
Metformin also inhibits monocyte adhesion to the endo-
thelium which is one of the factors causing arthrosclerosis
in the vessels. It decreases the adhesion molecule expre-
ssion in the endothelium including Vascular Cell Adhes-
ion Molecule 1 (VCAM 1), Intracellular Adhesion Mol-
ecule 1 (ICAM 1) and E- selection27.
4. Effects of Metformin on haemostatic factors:
In patients with type 2 diabetes, metformin improves
the markers of endothelial dysfunction and inflammatory
activity including von-willebrand factor, selectin tissue
type plasminogen activators and plasminogen activator
inhibitor 1.6, 28  It is also found to improve the endothelial
regulators of hemostasis (vWf), leukocyte adhesion
molecules (SE selectin , VCAM 1) and fibrinolytic
agents (tPA, PAI).29
5. Effects of Metformin on platelets:
The anti atherosclerotic and cardio protective effects of
metformin by its action on platelets have recently been
confirmed in both prospective and retrospective studies.
Metfomin has direct effect on two important component
of an arterial thrombus that is fibrin and platelets. It acts
by inhibiting two important platelet activating factors;
PAF4 and B7G thus causing decrease in platelet plug
formation.30,31
6. Effects of Metformin on fatty acids:
The storage of free fatty acids in the endothelium is
increased in insulin resistance state.  Metformin in turn
promotes free fatty acid oxidation in the endothelial
tissue by its ability to activate endothelial AMP protein
kinase.5, 32 Metformin decreases lipoprotein lipase
production and thus decrease the breakdown of LDL
into VLDL, accounting for further vasculoprotective
effects. LDL is taken up by liver due to presence of its
receptors on hepatocytes thus decreasing VLDL in blood.
It also reduces endothelial permeability and edema and
thus improves capillary functions33.
7. Effects of Metformin on inflammation:
Metformin along with other effects, also decreases
inflammatory mediators such as tissue plasminogen
activator (tPA), antigen factors 7 and 13, and C-reactive
protein (CRP) levels34.
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8. Additional effects of Metformin:
Type 2 diabetes mellitus patients being treated with
metformin have shown slowing of annual progression
of carotid intima indicating that this drug decreases the
normal carotid changes in these patients.35 It has been
documented that metformin treatment produces
significant reduction in multiple factors leading to
decrease in brachial artery diameter at base line; brachial
artery diameter after reactive hyperthermia, abnormal
flow mediated dilation and increased intima media
thickness.36, 37 In addition,  plasma concentration of
endothelin 1 which is one of the main biological markers
of endothelial function is significantly altered in
polycystic ovarian syndrome patients, has been found
to decrease with metformin therapy.38 At cellular level
specifically in mitochondrial chain, it also prevents
apoptosis, which is another mechanism to explain the
long term vascular protection afforded by metformin.39
A study on obese insulin resistant cases has documented
that metformin promotes a prolonged post prandial fall
in the plasma levels of the gut hormone “ghrelin” which
stimulates food intake and encourages adiposity .Thus
metformin decreases caloric intake and helps in total
weight reduction in  type 2 diabetes.40
CONCLUSION:
Metformin provides vasculo-protective cover and delays
the vascular changes in type 2 diabetic patients in addition
to provision of good control of glycemic levels with
least side effects. These vasculo-protective effects make
metformin a novel drug in the class of oral anti-diabetics.
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